1. Home
  2. MRKR vs SAG Comparison

MRKR vs SAG Comparison

Compare MRKR & SAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • SAG
  • Stock Information
  • Founded
  • MRKR N/A
  • SAG 1975
  • Country
  • MRKR United States
  • SAG Singapore
  • Employees
  • MRKR N/A
  • SAG N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • SAG
  • Sector
  • MRKR Health Care
  • SAG
  • Exchange
  • MRKR Nasdaq
  • SAG NYSE
  • Market Cap
  • MRKR 16.1M
  • SAG 7.1M
  • IPO Year
  • MRKR N/A
  • SAG 2024
  • Fundamental
  • Price
  • MRKR $1.18
  • SAG $0.62
  • Analyst Decision
  • MRKR Strong Buy
  • SAG
  • Analyst Count
  • MRKR 2
  • SAG 0
  • Target Price
  • MRKR $13.50
  • SAG N/A
  • AVG Volume (30 Days)
  • MRKR 239.7K
  • SAG 1.3M
  • Earning Date
  • MRKR 03-25-2025
  • SAG 12-19-2024
  • Dividend Yield
  • MRKR N/A
  • SAG N/A
  • EPS Growth
  • MRKR N/A
  • SAG N/A
  • EPS
  • MRKR N/A
  • SAG 0.21
  • Revenue
  • MRKR $5,395,849.00
  • SAG $56,387,000.00
  • Revenue This Year
  • MRKR $195.40
  • SAG N/A
  • Revenue Next Year
  • MRKR N/A
  • SAG N/A
  • P/E Ratio
  • MRKR N/A
  • SAG $3.26
  • Revenue Growth
  • MRKR 79.04
  • SAG N/A
  • 52 Week Low
  • MRKR $1.13
  • SAG $0.47
  • 52 Week High
  • MRKR $5.99
  • SAG $8.27
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 33.38
  • SAG N/A
  • Support Level
  • MRKR $1.35
  • SAG N/A
  • Resistance Level
  • MRKR $1.99
  • SAG N/A
  • Average True Range (ATR)
  • MRKR 0.22
  • SAG 0.00
  • MACD
  • MRKR 0.01
  • SAG 0.00
  • Stochastic Oscillator
  • MRKR 5.21
  • SAG 0.00

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About SAG SAG HOLDINGS LTD

SAG Holdings Ltd engages in the business of distributing automotive and industrial spare parts with operations primarily based in Singapore, and global sales primarily generated from the Middle East and Malaysia. Its business is comprised of On-Highway Business serving the automotive sector and Off-Highway Business primarily servicing the marine, energy, mining, construction, agriculture, and oil and gas sectors. The On-Highway Business Segment supply genuine and aftermarket spare parts to customers through our Autozone retail outlets located in Singapore, as well as Malaysia. The Off-Highway Business Segment supply a wide range of components and spare parts for internal combustion engines with a strong focus on filtration products through Filtec.

Share on Social Networks: